VivoSim Labs S-1/A details warrant cashless exercise dilution and Second Tranche conditions

Filed March 31, 2026 · Compared to S-1 Mar 27, 2026 · ~1 min read

Key Changes

• high

  New disclosure shows cashless exercise of common warrants could force issuance of up to 720.7M shares, far exceeding the 196.5M authorized shares available, risking inability to satisfy exercises.

  Risk Factors verify on EDGAR →
• high

  Common warrant exercise price set at 120% of the combined offering price, or $2.03 per share based on the assumed $1.69 price, with immediate exercisability and five-year term.

  Offering verify on EDGAR →
• medium

  Second Tranche closing now conditioned on stock price not falling below initial closing price and average daily trading volume of at least $100,000 over ten days, with purchase price at or above initial tranche.

  Offering verify on EDGAR →